The urgency of the COVID-19 pandemic highlighted the need for rapid, reliable real-world evidence (RWE) to guide public health and regulatory decisions. In response, a collaborative public-private partnership, including the FDA and Aetion, launched an initiative to leverage real-world data (RWD) for near real-time insights into the virus, its treatments, and its evolving clinical landscape.
This publication outlines the multi-phase approach taken to accelerate RWE generation during the COVID-19 pandemic. It includes strategies for selecting and analyzing fit-for-purpose RWD in a rapidly changing environment and the trial emulation methods used to ensure observational study validity amid evolving treatment protocols.
Through this research, we learn how cross-sector collaboration and real-time evidence generation informed public health decisions, paving the way for researchers to develop new tools and best practices to inform future public health responses.
Read the full article here.